CHILDREN'S ZYRTEC ALLERGY SYRUP OTC
Generic Name and Formulations:
Cetirizine HCl 1mg/mL; grape flavor, and bubble gum (sugar- and dye-free) flavor.
McNeil Consumer Healthcare
Indications for CHILDREN'S ZYRTEC ALLERGY SYRUP:
Adults and Children:
Chew tabs: may take with or without water. For doses <5mg: use syrup. <2yrs: not recommended. 2–6yrs: initially 2.5mg once daily; max 5mg once daily or 2.5mg every 12hrs. ≥6yrs: initially 5–10mg once daily. ≥65yrs: use chew tabs or syrup: 5mg once daily. Hepatic or renal impairment: individualize.
Hives Relief: not used for prevention or as a substitute for epinephrine. Hepatic or renal dysfunction. Pregnancy. Nursing mothers: not recommended.
Potentiates CNS depression with alcohol, other CNS depressants.
Drowsiness, somnolence, fatigue, dry mouth, pharyngitis. Children: headache, pharyngitis, GI upset/pain, cough, somnolence, diarrhea, epistaxis, bronchospasm, fatigue, irritability, insomnia.
Tabs—5, 14, 30, 45, 75; Liquid gels—12, 25, 40; Chew tabs 5mg—5, 10mg—12, 24; Hives Relief tabs—14; Syrup—4oz
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Undifferentiated Headaches Common in Children, Adolescents
- Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS
- Frontotemporal Dementia, Frontotemporal Lobar Degeneration Symptoms More Common Later in Life
- No Reduction in Cerebral Perfusion With Intensive Blood Pressure Lowering
- Successful Delirium Prevention in Critically Ill With Dexmedetomidine